

Ref. No: FOI1619
Date: 20/03/2025
Subject: Advanced Ovarian Cancer

REQUEST

1. How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months?
(a) If none, do you refer advanced ovarian cancer patients to another trust, and if so which one?
2. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:
 - Paclitaxel in combination with a platinum-based compound
 - Platinum-based therapy alone (cisplatin or carboplatin)
 - Bevacizumab in combination with paclitaxel and carboplatin
 - Olaparib
 - Olaparib + Bevacizumab
 - Niraparib
 - Rucaparib
3. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part
4. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with:
 - Olaparib
 - Olaparib + Bevacizumab
 - Niraparib
 - Other treatments

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

1. How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months?

Time period, latest available (01.11.24 – 31.01.25)

St Helen's & Knowsley	Southport & Ormskirk
< 5	0

<5

Due to the low number of patients which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.

b. If none, do you refer advanced ovarian cancer patients to another trust, and if so which one?

Patients are referred to Liverpool Women's Hospital and Clatterbridge Cancer Centre for treatment of this cancer type.

2. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:

- Paclitaxel in combination with a platinum-based compound
- Platinum-based therapy alone (cisplatin or carboplatin)
- Bevacizumab in combination with paclitaxel and carboplatin
- Olaparib

- **Olaparib + Bevacizumab**
- **Niraparib**
- **Rucaparib**

There were no patients in this category treated at either site in this time period.